S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
RCUS · Arcus Biosciences, Inc.
NEW YORK STOCK EXCHANGE, INC. - Real Time Price • USD
Arcus Biosciences Inc (RCUS)
NEW YORK STOCK EXCHANGE, INC.
Biotechnology
$19.08
-4.67
(-19.66%)
● At close: October 21 at 4:00:00 PM EDT
$17.88
-1.22
(-6.39%)
After-Hours:
5:15:43 PM EDT
DAY'S RANGE
$19.08
$18.98
$24.24
52-WEEK RANGE
$19.08
$16.35
$31.73
What's happening
- RCUS is down 19.66% today, trading at $19.08. — Live quote
- Volume today (253,875) is well below its 3-month average of 1,483,860. (Finnhub fundamentals)
- Reports earnings on 2026-11-10 (after market close), 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.72 actual vs. $-0.92 estimated (+21.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 11
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RCUS
-0.34%
vs S&P 500
-13.11%
1-YEAR RETURN
RCUS
+35.95%
vs S&P 500
+21.39%
6-MONTH RETURN
RCUS
+0.68%
3-MONTH RETURN
RCUS
-19.44%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.72
Est. $-0.92
BEAT +21.4%
2026-04-26 (Q1 2026)
$-1.02
Est. $-0.89
MISS -14.0%
2026-01-26 (Q4 2025)
$-0.89
Est. $-1.05
BEAT +15.0%
2025-10-26 (Q3 2025)
$-1.27
Est. $-1.34
BEAT +5.0%
Valuation Measures & Ratios
Enterprise Value4$3.03B
Forward P/E5—
PEG Ratio6-0.24
Price / Sales (TTM1)26.28
Price / Book78.36
EV4 / Revenue25.86
EV4 / EBITDA37.17
Profit Margin-393.16%
Operating Margin-415.38%
Return on Equity (ROE8)-89.54%
Return on Assets (ROA9)-45.61%
Avg Volume (3M)1,483,860
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $3.90B | $2.71B | $1.45B | — | $772.7M |
| P/E | -11.02 | -7.23 | -4.27 | — | -2.57 |
| Price/Sales | 15.98 | 11.75 | 5.52 | — | 2.97 |
| Price/Book | 8.40 | 5.18 | 3.32 | — | 1.46 |
| EV/Revenue | 15.78 | 11.31 | 4.99 | — | 2.42 |
| ROE | -76.29% | -71.56% | -77.75% | — | -56.69% |
| ROA | -38.31% | -37.61% | -34.80% | — | -26.04% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short13,110,576
Change from Prior Settlement-5.08%
% of Float—
Days to Cover (Short Ratio)7.64
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +35.9%. Finnhub market metrics ↗
- Latest SEC filing is Form 8-K, filed 2026-10-20; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -74.4% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -393.2%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RCUS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41.0M | $17.0M | $26.0M | $160.0M | $28.0M | $48.0M | $39.0M | $145.0M |
| Operating income | -$96.0M | -$134.0M | -$142.0M | -$8.0M | -$122.0M | -$105.0M | -$106.0M | -$16.0M |
| Net income | -$91.0M | -$128.0M | -$135.0M | $0 | -$112.0M | -$92.0M | -$93.0M | -$4.0M |
| EPS (diluted) | $-0.72 | $-1.02 | $-1.27 | $0.00 | $-1.14 | $-1.00 | $-1.02 | $-0.05 |
| EPS (basic) | $-0.72 | $-1.02 | $-1.27 | $0.00 | $-1.14 | $-1.00 | $-1.02 | $-0.05 |
| Operating margin | -$234 | -$788 | -$546 | -$5 | -$436 | -$219 | -$272 | -$11 |
| Net margin | -$222 | -$753 | -$519 | $0 | -$400 | -$192 | -$238 | -$3 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $924.0M | $997.0M | $1.14B | $974.0M | $1.07B | $1.16B | $1.15B | $1.25B |
| Total liabilities | — | — | — | — | — | — | — | — |
| Stockholders' equity | $464.0M | $524.0M | $631.0M | $436.0M | $549.0M | $531.0M | $485.0M | $565.0M |
| Total current assets | $756.0M | $844.0M | $1.01B | $857.0M | $946.0M | $1.03B | $1.02B | $1.13B |
| Total current liabilities | $198.0M | $209.0M | $231.0M | $235.0M | $210.0M | $192.0M | $226.0M | $215.0M |
| Cash & equivalents | $150.0M | $201.0M | $222.0M | $238.0M | $248.0M | $192.0M | $150.0M | $201.0M |
| Property, plant & equipment | $36.0M | $38.0M | $40.0M | $42.0M | $44.0M | $46.0M | $47.0M | $48.0M |
| Other non-current assets | $59.0M | $61.0M | $63.0M | $65.0M | $69.0M | $71.0M | $73.0M | $75.0M |
| Accounts payable | $34.0M | $39.0M | $42.0M | $42.0M | $29.0M | $22.0M | $18.0M | $13.0M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | $19.0M | $34.0M | $35.0M | $52.0M | $71.0M | $72.0M | $85.0M | $105.0M |
| Other current liabilities | $145.0M | $136.0M | $154.0M | $141.0M | $110.0M | $98.0M | $123.0M | $97.0M |
| Long-term debt | $101.0M | $100.0M | $99.0M | $98.0M | $97.0M | $48.0M | $48.0M | $47.0M |
| Other non-current liabilities | $124.0M | $119.0M | $135.0M | $152.0M | $159.0M | $166.0M | $157.0M | $136.0M |
| Common stock & paid-in capital | $2.17B | $2.14B | $2.12B | $1.81B | $1.79B | $1.77B | $1.62B | $1.60B |
| Retained earnings | -$1.70B | -$1.61B | -$1.49B | -$1.38B | -$1.24B | -$1.24B | -$1.13B | -$1.04B |
| Accumulated other comprehensive income (loss) | -$1.0M | -$1.0M | $0 | — | — | — | — | $1.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$119.0M | -$138.0M | -$120.0M | -$97.0M | -$133.0M | -$132.0M | -$100.0M | $26.0M |
| Investing cash flow | $52.0M | $114.0M | -$182.0M | $79.0M | $137.0M | $32.0M | $51.0M | -$29.0M |
| Financing cash flow | $16.0M | $3.0M | $286.0M | $8.0M | $52.0M | $142.0M | -$2.0M | $48.0M |
| Free cash flow | -$119.0M | -$138.0M | -$121.0M | -$97.0M | -$133.0M | -$133.0M | -$101.0M | $25.0M |
| Capital expenditures | $0 | $0 | $1.0M | $0 | $0 | $1.0M | $1.0M | $1.0M |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $15.0M | $19.0M | $15.0M | $14.0M | $15.0M | $16.0M | $17.0M | $19.0M |
| Change in accounts payable | -$5.0M | -$3.0M | $0 | $13.0M | $8.0M | $3.0M | $5.0M | -$1.0M |
| Purchases of investments | $182.0M | $150.0M | $397.0M | $165.0M | $161.0M | $353.0M | $172.0M | $278.0M |
| Other investing activities | — | — | — | — | — | — | $0 | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | $0 | $0 | $0 | — | $5.0M | $1.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $247.0M | $258.0M | $117.0M | $112.0M | — |
| Operating income | -$386.0M | -$330.0M | -$340.0M | -$280.0M | $54.0M |
| Net income | -$353.0M | -$283.0M | -$307.0M | -$267.0M | $53.0M |
| EPS (diluted) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 |
| EPS (basic) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.76 |
| Operating margin | -$156 | -$128 | -$291 | -$250 | — |
| Net margin | -$143 | -$110 | -$262 | -$238 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.14B | $1.15B | $1.09B | $1.34B | $1.59B |
| Total liabilities | — | — | — | — | $750.4M |
| Stockholders' equity | $631.0M | $485.0M | $462.0M | $657.0M | $842.0M |
| Total current assets | $1.01B | $1.02B | $831.0M | $1.07B | $1.26B |
| Total current liabilities | $231.0M | $226.0M | $184.0M | $193.0M | $166.0M |
| Cash & equivalents | $222.0M | $150.0M | $127.0M | $206.0M | $148.0M |
| Property, plant & equipment | $40.0M | $47.0M | $51.0M | $35.0M | $32.0M |
| Other non-current assets | $63.0M | $73.0M | $106.0M | $114.0M | $116.0M |
| Accounts payable | $42.0M | $18.0M | $17.0M | $20.0M | $10.0M |
| Accrued liabilities | — | — | — | — | $24.2M |
| Deferred revenue (current) | $35.0M | $85.0M | $91.0M | $97.0M | $102.0M |
| Other current liabilities | $154.0M | $123.0M | $76.0M | $76.0M | $54.0M |
| Long-term debt | $99.0M | $48.0M | $0 | — | — |
| Other non-current liabilities | $135.0M | $157.0M | $142.0M | $140.0M | $122.0M |
| Common stock & paid-in capital | $2.12B | $1.62B | $1.31B | $1.21B | $1.12B |
| Retained earnings | -$1.49B | -$1.13B | -$849.0M | -$542.0M | -$275.0M |
| Accumulated other comprehensive income (loss) | — | — | $0 | -$7.0M | -$1.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$482.0M | -$170.0M | -$306.0M | $438.0M | -$256.0M |
| Investing cash flow | $66.0M | -$84.0M | $194.0M | -$413.0M | -$4.0M |
| Financing cash flow | $488.0M | $277.0M | $33.0M | $33.0M | $237.0M |
| Free cash flow | -$484.0M | -$176.0M | -$330.0M | $432.0M | -$282.0M |
| Capital expenditures | $2.0M | $6.0M | $24.0M | $6.0M | $26.0M |
| Share-based compensation | $60.0M | $76.0M | $73.0M | $65.0M | $55.0M |
| Change in accounts payable | $24.0M | $3.0M | -$1.0M | $8.0M | -$5.0M |
| Purchases of investments | $1.08B | $1.04B | $788.0M | $1.24B | $719.0M |
| Other investing activities | — | $0 | $0 | $3.0M | — |
| Share repurchases | — | — | — | — | — |
| Tax withholding on stock comp | $0 | $7.0M | $0 | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RCUS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers85.1%
Shares Outstanding127,000,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 31,424,760 | $968.8M | 24.74% | +0.0% | 2026-08-03 |
| BlackRock, Inc. | 16,416,249 | $506.1M | 12.93% | +7.8% | 2026-08-07 |
| State Street Corp | 6,029,484 | $185.9M | 4.75% | +11.4% | 2026-08-07 |
| WELLINGTON MANAGEMENT GROUP LLP | 5,895,448 | $181.8M | 4.64% | -3.2% | 2026-08-14 |
| MONTANOVA CAPITAL, LLC | 4,776,423 | $147.3M | 3.76% | -5.1% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,475,528 | $138.0M | 3.52% | +4.8% | 2026-06-30 |
| FMR LLC | 4,049,757 | $124.9M | 3.19% | +247.5% | 2026-08-13 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,888,346 | $119.9M | 3.06% | +0.8% | 2026-06-30 |
| CITADEL ADVISORS LLC | 3,135,057 | $96.7M | 2.47% | +135.7% | 2026-08-14 |
| Woodline Partners LP | 3,007,798 | $92.7M | 2.37% | -20.4% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,448,749 | $75.5M | 1.93% | +8.7% | 2026-08-12 |
| Siren, L.L.C. | 2,420,430 | $74.6M | 1.91% | -19.5% | 2026-08-13 |
| Fisher Asset Management, LLC | 2,139,396 | $66.0M | 1.68% | -2.3% | 2026-08-04 |
| MARSHALL WACE, LLP | 1,945,088 | $60.0M | 1.53% | -48.3% | 2026-08-13 |
| SAMLYN CAPITAL, LLC | 1,547,182 | $47.7M | 1.22% | -18.9% | 2026-08-14 |
| DIMENSIONAL FUND ADVISORS LP | 1,434,320 | $44.2M | 1.13% | +0.6% | 2026-08-11 |
| BNP Paribas Asset Management Holding S.A. | 1,419,533 | $43.8M | 1.12% | -14.2% | 2026-08-12 |
| Goldman Sachs Group Inc | 1,387,566 | $42.8M | 1.09% | +38.8% | 2026-08-14 |
| Soleus Capital Management, L.P. | 1,168,738 | $36.0M | 0.92% | +158.6% | 2026-08-11 |
| Sofinnova Investments, Inc. | 945,690 | $29.2M | 0.74% | +2.4% | 2026-08-14 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 941,756 | $29.0M | 0.74% | +4.2% | 2026-08-14 |
| Northern Trust Corp | 932,523 | $28.7M | 0.73% | +11.0% | 2026-08-12 |
| Parkman Healthcare Partners LLC | 919,266 | $28.3M | 0.72% | -23.9% | 2026-08-14 |
| Invesco Ltd. | 845,233 | $26.1M | 0.67% | +3.0% | 2026-08-13 |
| BAKER BROS. ADVISORS LP | 844,816 | $26.0M | 0.67% | +103.3% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-16 to 2026-08-21
Recent transactions
- Insiders have net sold 113,152 shares over the last 182 days, across 0 purchases and 10 sales.
- Most recent: Azoy Alexander (Chief Accounting Officer) — Option exercise of 2,827 shares on 2026-08-21.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)113,152 sh(10 txns)
Net Shares-113,152
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Azoy Alexander | Chief Accounting Officer | Option exercise | 2026-08-21 | 2,827 |
| Jaen Juan C. | President | Open market sale | 2026-07-10 | 19,799 |
| Lambert Nicole | Director | Grant / award | 2026-06-11 | 5,700 |
| Machado Patrick | Director | Grant / award | 2026-06-11 | 5,700 |
| KANEKO YASUNORI | Director | Grant / award | 2026-06-11 | 5,700 |
| Tang Carolyn C. | General Counsel | Option exercise | 2026-06-11 | 34,090 |
| Lacey David L. | Director | Grant / award | 2026-06-11 | 5,700 |
| FALBERG KATHRYN E | Director | Grant / award | 2026-06-11 | 5,700 |
| Ribas Antoni | Director | Grant / award | 2026-06-11 | 5,700 |
| PERLMAN ANDREW J | Director | Grant / award | 2026-06-11 | 5,700 |
| Goeltz II Robert C. | Chief Financial Officer | Open market sale | 2026-05-11 | 7,763 |
| Markus Richard | Chief Medical Officer | Grant / award | 2026-01-23 | 24,000 |
| ROSEN TERRY J | Chief Executive Officer | Grant / award | 2026-01-23 | 79,000 |
| Jarrett Jennifer | Chief Operating Officer | Grant / award | 2026-01-23 | 31,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-21 | Azoy Alexander | Chief Accounting Officer | Option exercise | 2,827 | $15.44 |
| 2026-08-21 | Azoy Alexander | Chief Accounting Officer | Open market sale | 2,827 | $30.00 |
| 2026-07-10 | Jaen Juan C. | President | Open market sale | 19,799 | $28.61 |
| 2026-07-10 | Jaen Juan C. | President | Open market sale | 268 | $29.40 |
| 2026-07-09 | Jaen Juan C. | President | Open market sale | 48,502 | $30.05 |
| 2026-06-24 | Jaen Juan C. | President | Open market sale | 6,431 | $29.66 |
| 2026-06-23 | Jaen Juan C. | President | Open market sale | 14,067 | $27.69 |
| 2026-06-23 | Jaen Juan C. | President | Open market sale | 1,697 | $28.06 |
| 2026-06-22 | Jaen Juan C. | President | Open market sale | 9,236 | $27.03 |
| 2026-06-11 | Lambert Nicole | Director | Grant / award | 5,700 | $0.00 |
| 2026-06-11 | Machado Patrick | Director | Grant / award | 5,700 | $0.00 |
| 2026-06-11 | KANEKO YASUNORI | Director | Grant / award | 5,700 | $0.00 |
| 2026-06-11 | Tang Carolyn C. | General Counsel | Option exercise | 34,090 | $2.57 |
| 2026-06-11 | Lacey David L. | Director | Grant / award | 5,700 | $0.00 |
| 2026-06-11 | FALBERG KATHRYN E | Director | Grant / award | 5,700 | $0.00 |
| 2026-06-11 | Ribas Antoni | Director | Grant / award | 5,700 | $0.00 |
| 2026-06-11 | PERLMAN ANDREW J | Director | Grant / award | 5,700 | $0.00 |
| 2026-06-01 | Azoy Alexander | Chief Accounting Officer | Open market sale | 2,562 | $25.77 |
| 2026-05-11 | Goeltz II Robert C. | Chief Financial Officer | Open market sale | 7,763 | $25.63 |
| 2026-01-23 | Markus Richard | Chief Medical Officer | Grant / award | 24,000 | $0.00 |
| 2026-01-23 | ROSEN TERRY J | Chief Executive Officer | Grant / award | 79,000 | $0.00 |
| 2026-01-23 | Jaen Juan C. | President | Grant / award | 31,000 | $0.00 |
| 2026-01-23 | Tang Carolyn C. | General Counsel | Grant / award | 24,000 | $0.00 |
| 2026-01-23 | Goeltz II Robert C. | Chief Financial Officer | Grant / award | 24,000 | $0.00 |
| 2026-01-23 | Azoy Alexander | Chief Accounting Officer | Grant / award | 21,050 | $0.00 |
| 2026-01-23 | Jarrett Jennifer | Chief Operating Officer | Grant / award | 31,000 | $0.00 |
| 2026-01-08 | ROSEN TERRY J | Chief Executive Officer | Gift | 35,000 | $0.00 |
| 2026-01-05 | Jaen Juan C. | President | Open market sale | 29,670 | $21.34 |
| 2026-01-05 | Jaen Juan C. | President | Open market sale | 2,053 | $22.34 |
| 2026-01-05 | Jaen Juan C. | President | Open market sale | 100 | $23.20 |
| 2025-12-31 | Goeltz II Robert C. | Chief Financial Officer | Open market sale | 6,552 | $23.38 |
| 2025-12-30 | ROSEN TERRY J | Chief Executive Officer | Gift | 2,400 | $0.00 |
| 2025-12-16 | Ribas Antoni | Director | Gift | 5,050 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 19:09 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-20 | 8-K | 2026-10-20 | View on SEC.gov → |
| 2026-08-24 | 4 | 2026-08-21 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-07-13 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-22 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
Recent news
Headlines about RCUS (Arcus Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Arcus launches stock offering to fund kidney cancer drug push
Dealroom · 2026-10-21 -
Citi reiterates buy rating on Arcus Biosciences after stock drops 20%
StreetInsider · 2026-10-21 -
Arcus Biosciences officers face investigation f...
Pluang · 2026-10-21 -
Arcus Biosciences launches public offering of common stock By Investing.com
Investing.com Canada · 2026-10-21 -
Arcus Biosciences announces public stock offering
Seeking Alpha · 2026-10-21 -
Arcus Biosciences launches public offering of common stock
StreetInsider · 2026-10-21 -
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Yahoo Finance · 2026-10-21 -
A public stock offering has begun at Arcus Biosciences, but its size and completion remain uncertain.
Stock Titan · 2026-10-21
No headlines in this category right now — try “All”.